Novo Nordisk (NVO) said Friday that Health Canada has accepted for review a supplemental new drug submission for semaglutide 2.4 mg as a once weekly treatment for people with metabolic dysfunction-associated steatohepatitis.
MASH is a chronic, progressive metabolic disease affecting the liver, which can be potentially life-threatening if not properly managed.
The drug has been accepted for review under Health Canada's priority review policy, Novo said.
The company said semaglutide injection 2.4 mg is approved by Health Canada for chronic weight management and non-fatal myocardial infarction risk reduction in some adults.
Novo shares were rising nearly 5% in recent trading.
Price: 68.67, Change: +3.07, Percent Change: +4.68
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.